{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:20:28Z","timestamp":1785154828293,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R34DA047660"],"award-info":[{"award-number":["1R34DA047660"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.dadr.2023.100213","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T03:58:43Z","timestamp":1703303923000},"page":"100213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs"],"prefix":"10.1016","volume":"10","author":[{"given":"J.I.","family":"Tsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Gojic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.L.","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.C.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Radick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.R.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sandvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Taber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ninburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.","family":"Kubiniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Stekler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4221-1362","authenticated-orcid":false,"given":"E.J.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.dadr.2023.100213_bib0001","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1177\/1060028016653608","article-title":"The continuum of pharmacist prescriptive authority","volume":"50","author":"Adams","year":"2016","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.dadr.2023.100213_bib0002","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.japh.2017.01.006","article-title":"Implementing take-home naloxone in an urban community pharmacy","volume":"57","author":"Akers","year":"2017","journal-title":"J. Am. Pharm. Assoc."},{"issue":"suppl_2","key":"10.1016\/j.dadr.2023.100213_bib0003","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/cid\/cit305","article-title":"Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study","volume":"57","author":"Alavi","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"23","key":"10.1016\/j.dadr.2023.100213_bib0004","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers","volume":"364","author":"Arora","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.dadr.2023.100213_bib0005","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/jvh.12393","article-title":"Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement","volume":"22","author":"Artenie","year":"2015","journal-title":"J. Viral Hepat."},{"issue":"9","key":"10.1016\/j.dadr.2023.100213_bib0006","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians' views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.dadr.2023.100213_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103924","article-title":"Barriers and facilitators to implementing a pharmacist, physician, and patient navigator-collaborative care model (PPP-CCM) to treat hepatitis C among people who inject drugs","volume":"111","author":"Austin","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.dadr.2023.100213_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108684","article-title":"Health care-seeking experiences for people who inject drugs with hepatitis C: qualitative explorations of stigma","volume":"137","author":"Austin","year":"2022","journal-title":"J. Subst. Abuse Treat."},{"issue":"6","key":"10.1016\/j.dadr.2023.100213_bib0009","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1215\/03616878-10041121","article-title":"Improving access to high-value, high-cost medicines: the use of subscription models to treat hepatitis C using direct-acting antivirals in the United States","volume":"47","author":"Auty","year":"2022","journal-title":"J. Health Polit. Policy Law"},{"issue":"8","key":"10.1016\/j.dadr.2023.100213_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.2291","article-title":"Medicaid subscription-based payment models and implications for access to hepatitis C medications","volume":"2","author":"Auty","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.dadr.2023.100213_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","article-title":"Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program","volume":"75","author":"Butner","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.dadr.2023.100213_bib0012","series-title":"Hepatitis C: State of Medicaid Access","year":"2023"},{"key":"10.1016\/j.dadr.2023.100213_bib0013","unstructured":"Centers for Disease Control and Prevention, 2013. Collaborative practice agreements and pharmacists\u2019 patient care services: a resource for pharmacists. https:\/\/www.cdc.gov\/dhdsp\/pubs\/docs\/translational_tools_pharmacists.pdf. (Accessed April 3, 2023)."},{"key":"10.1016\/j.dadr.2023.100213_bib0014","unstructured":"Centers for Disease Control and Prevention, 2020. Hepatitis C surveillance 2020 https:\/\/www.cdc.gov\/hepatitis\/statistics\/2020surveillance\/hepatitis-c.htm. (Accessed August 22, 2023)."},{"key":"10.1016\/j.dadr.2023.100213_bib0015","unstructured":"Centers for Medicare & Medicaid Services, 2019. CMS approves Washington State plan amendment proposal to allow supplemental rebates involving a \u201cSubscription\u201d model for prescription drug payment in medicaid | CMS. https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-approves-washington-state-plan-amendment-proposal-allow-supplemental-rebates-involving. (Accessed April 3, 2023)."},{"issue":"11","key":"10.1016\/j.dadr.2023.100213_bib0016","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.dadr.2023.100213_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108525","article-title":"Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington","volume":"220","author":"Corcorran","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.dadr.2023.100213_bib0018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.13949","article-title":"Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework","volume":"39","author":"Day","year":"2019","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.dadr.2023.100213_bib0019","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.japh.2022.04.014","article-title":"Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center","volume":"62","author":"Downes","year":"2022","journal-title":"J. Am. Pharm. Assoc."},{"issue":"15","key":"10.1016\/j.dadr.2023.100213_bib0020","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2023.3692","article-title":"A national hepatitis C elimination program in the United States: a historic opportunity","volume":"329","author":"Fleurence","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.dadr.2023.100213_bib0021","article-title":"With a promising new plan to pay for pricey cures, two states set out to eliminate hepatitis C. But cost hasn't been the biggest problem","author":"Florko","year":"2022","journal-title":"Stat"},{"key":"10.1016\/j.dadr.2023.100213_bib0022","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.drugalcdep.2017.10.011","article-title":"Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington","volume":"182","author":"Glick","year":"2018","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.dadr.2023.100213_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cld.1150","article-title":"HCV elimination in the US Department of veterans affairs","volume":"18","author":"Gonzalez","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.dadr.2023.100213_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103469","article-title":"Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs","volume":"96","author":"Grebely","year":"2021","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.dadr.2023.100213_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12954-015-0058-x","article-title":"Orienting patients to greater opioid safety: models of community pharmacy-based naloxone","volume":"12","author":"Green","year":"2015","journal-title":"Harm. Reduct. J."},{"key":"10.1016\/j.dadr.2023.100213_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"issue":"2","key":"10.1016\/j.dadr.2023.100213_bib0027","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"issue":"7","key":"10.1016\/j.dadr.2023.100213_bib0028","doi-asserted-by":"crossref","first-page":"856","DOI":"10.18553\/jmcp.2021.27.7.856","article-title":"Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis","volume":"27","author":"Herink","year":"2021","journal-title":"JMCP"},{"issue":"3","key":"10.1016\/j.dadr.2023.100213_bib0029","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.dadr.2023.100213_bib0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/00333549211015664","article-title":"Outcomes of a pharmacist-led hepatitis C virus treatment program in an urban safety-net health system, Chicago, 2017-2019","volume":"137","author":"Hunt","year":"2022","journal-title":"Public Health Rep."},{"issue":"5","key":"10.1016\/j.dadr.2023.100213_bib0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.dadr.2023.100213_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/apc.2019.0235","article-title":"A pharmacist-led, same-day, HIV pre-exposure prophylaxis initiation program to increase PrEP uptake and decrease time to PrEP initiation","volume":"34","author":"Khosropour","year":"2020","journal-title":"AIDS Patient Care STDS"},{"issue":"7","key":"10.1016\/j.dadr.2023.100213_bib0033","doi-asserted-by":"crossref","first-page":"ofz316","DOI":"10.1093\/ofid\/ofz316","article-title":"Expanding hepatitis C virus care and cure: national experience using a clinical pharmacist\u2013Driven model","volume":"6","author":"Koren","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"9","key":"10.1016\/j.dadr.2023.100213_bib0034","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"issue":"3","key":"10.1016\/j.dadr.2023.100213_bib0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1370\/afm.2069","article-title":"A hepatitis C treatment program based in a safety-net hospital patient-centered medical home","volume":"15","author":"Lasser","year":"2017","journal-title":"Ann. Fam. Med."},{"issue":"4","key":"10.1016\/j.dadr.2023.100213_bib0036","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1074\/jbc.M110.168286","article-title":"HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NF\u03baB","volume":"286","author":"Lin","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.dadr.2023.100213_bib0037","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","article-title":"Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial","volume":"7","author":"Litwin","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.dadr.2023.100213_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207226","article-title":"Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs?","volume":"13","author":"Madden","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.dadr.2023.100213_bib0039","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients: the addiction severity index","volume":"168","author":"McLellan","year":"1980","journal-title":"J. Nerv. Ment. Dis."},{"issue":"4","key":"10.1016\/j.dadr.2023.100213_bib0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1037\/0893-164X.9.4.242","article-title":"Reliability of self-reported HIV risk behaviors of drug users","volume":"9","author":"Needle","year":"1995","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.dadr.2023.100213_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108438","article-title":"Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings","volume":"131","author":"Ngo","year":"2021","journal-title":"J. Subst. Abuse Treat."},{"issue":"10","key":"10.1016\/j.dadr.2023.100213_bib0042","doi-asserted-by":"crossref","first-page":"ofaa377","DOI":"10.1093\/ofid\/ofaa377","article-title":"Low adherence achieves high HCV cure rates among people who inject drugs treated with direct-acting antiviral agents","volume":"7","author":"Norton","year":"2020","journal-title":"Open Forum Infect. Dis."},{"issue":"50","key":"10.1016\/j.dadr.2023.100213_bib0043","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls \u2014 United States, 2019\u20132020","volume":"70","author":"O'Donnell","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.dadr.2023.100213_bib0044","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/IPRP.S169282","article-title":"Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV\/HCV coinfection","volume":"7","author":"Olea","year":"2018","journal-title":"IPRP"},{"issue":"4","key":"10.1016\/j.dadr.2023.100213_bib0045","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Glob. Health"},{"issue":"4","key":"10.1016\/j.dadr.2023.100213_bib0046","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/00952990.2022.2081923","article-title":"Trends in characteristics of fentanyl-related poisonings in the United States, 2015-2021","volume":"48","author":"Palamar","year":"2022","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"5","key":"10.1016\/j.dadr.2023.100213_bib0047","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.japh.2022.03.015","article-title":"Pharmacy naloxone codispensing: a mixed methods study of practices and perspectives under a statewide standing order program","volume":"62","author":"Pollini","year":"2022","journal-title":"J. Am. Pharm. Assoc."},{"issue":"9","key":"10.1016\/j.dadr.2023.100213_bib0048","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2468-1253(20)30120-5","article-title":"Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial","volume":"5","author":"Radley","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.dadr.2023.100213_bib0049","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/jalm\/jfac041","article-title":"Investigation of fentanyl usage in the Seattle Area","volume":"7","author":"Reinhart","year":"2022","journal-title":"J. Appl. Lab. Med."},{"issue":"8","key":"10.1016\/j.dadr.2023.100213_bib0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1258\/jtt.2012.gth113","article-title":"Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States","volume":"18","author":"Scott","year":"2012","journal-title":"J. Telemed. Telecare"},{"issue":"6","key":"10.1016\/j.dadr.2023.100213_bib0051","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dadr.2023.100213_bib0052","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12325-020-01535-3","article-title":"Estimating the year each state in the United States will achieve the World Health Organization's elimination targets for hepatitis C","volume":"38","author":"Sulkowski","year":"2021","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.dadr.2023.100213_bib0053","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/cid\/ciac139","article-title":"Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014\u20132020","volume":"75","author":"Teshale","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.dadr.2023.100213_bib0054","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13722-021-00260-8","article-title":"Treat my whole person, not just my condition\u2019: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs","volume":"16","author":"Tsui","year":"2021","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.dadr.2023.100213_bib0055","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugalcdep.2018.11.026","article-title":"Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle","volume":"195","author":"Tsui","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.dadr.2023.100213_bib0056","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1071\/SH18084","article-title":"Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care","volume":"15","author":"Tung","year":"2018","journal-title":"Sex. Health"},{"key":"10.1016\/j.dadr.2023.100213_bib0057","series-title":"Hepatitis C Online","year":"2023"},{"key":"10.1016\/j.dadr.2023.100213_bib0058","series-title":"Eliminating Hepatitis C","year":"2020"},{"issue":"4","key":"10.1016\/j.dadr.2023.100213_bib0059","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0149-7189(94)90035-3","article-title":"Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach","volume":"17","author":"Weatherby","year":"1994","journal-title":"Eval. Program Plann."},{"key":"10.1016\/j.dadr.2023.100213_bib0060","series-title":"Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis","year":"2016"},{"issue":"2","key":"10.1016\/j.dadr.2023.100213_bib0061","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/add.15641","article-title":"Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial","volume":"117","author":"Wu","year":"2022","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.dadr.2023.100213_bib0062","doi-asserted-by":"crossref","first-page":"364","DOI":"10.18553\/jmcp.2017.23.3.364","article-title":"Outcomes of pharmacy-led hepatitis C direct-acting antiviral utilization management at a veterans affairs medical center","volume":"23","author":"Yang","year":"2017","journal-title":"JMCP"}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724623000835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724623000835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:32:02Z","timestamp":1757421122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724623000835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":62,"alternative-id":["S2772724623000835"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2023.100213","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2023.100213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100213"}}